...plc (LSE:OXP) $31.5 Abzena plc $31.3 SciFluor Life Sciences Inc. $30.0 AMO Pharma Ltd. $25.0 NovaBiotics Ltd....

...plc (LSE:OXP) $31.5 Abzena plc $31.3 SciFluor Life Sciences Inc. $30.0 AMO Pharma Ltd. $25.0 NovaBiotics Ltd....

...The company hopes to start a Phase III trial of the dual mucoactive-antibacterial in 1H19. NovaBiotics...
...of CARE CF 1 were safety and the change from baseline in sputum bacterial load. NovaBiotics...
...plus SOC led to numeric reductions in sputum neutrophil elastase and C-reactive protein (CRP) levels. NovaBiotics Ltd....

...the endogenous human protein kininogen, which is in Phase II for acute external otitis. And NovaBiotics Ltd....
...NASDAQ:DPRX), New York, N.Y. National Cancer Institute (NCI), Bethesda, Md. National Eye Institute, Bethesda, Md. NovaBiotics Ltd....

...CF. The product has Orphan Drug designation in the U.S. and EU to treat CF. NovaBiotics Ltd....

...FDA granted Orphan Drug designation to NovaBiotics' Lynovex cysteamine to treat cystic fibrosis. NovaBiotics is developing...
...are expected to start in 2H15. Lynovex also has Orphan Drug designation in the EU. NovaBiotics Ltd....

...Next quarter, NovaBiotics will begin a U.K. Phase IIa trial to evaluate a tablet formulation of...
...partly fund the trial. Lynovex has Orphan Drug designation in the EU to treat CF. NovaBiotics Ltd....

...Taro received an exclusive license to Novexatin . Taro and NovaBiotics' will co-develop the topical cyclic...
...treat onychomycosis along with other undisclosed development. The partners could not be reached for details. NovaBiotics Ltd....

...The European Commission granted Orphan Drug designation for NovaBiotics' Lynovex cysteamine to treat cystic fibrosis (CF...
...treat cystic fibrosis (CF). The dual mucoactive antibacterial is in preclinical testing for the indication. NovaBiotics Ltd....